Current status and future perspectives of immunotherapy in bladder cancer treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current status and future perspectives of immunotherapy in bladder cancer treatment
Authors
Keywords
-
Journal
Science China-Life Sciences
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-14
DOI
10.1007/s11427-020-1768-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies
- (2019) Tarek Taha et al. ONCOLOGIST
- Cancer immunotherapy may have a dark side
- (2019) Jocelyn Kaiser SCIENCE
- Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
- (2019) Jun Wang et al. NATURE MEDICINE
- The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability
- (2019) Jaegil Kim et al. EUROPEAN UROLOGY
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. CANCER CELL
- Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
- (2019) Dongkui Song et al. JOURNAL OF PATHOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy
- (2018) Alison M. Taylor et al. CANCER CELL
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Immune checkpoint inhibitors for metastatic bladder cancer
- (2018) Francesco Massari et al. CANCER TREATMENT REVIEWS
- Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
- (2018) Sachet A. Shukla et al. CELL
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
- (2018) Curtis H. Kugel et al. CLINICAL CANCER RESEARCH
- Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review
- (2018) Ashish M. Kamat et al. EUROPEAN UROLOGY
- Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy
- (2018) Mathieu F. Chevalier et al. EUROPEAN UROLOGY
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
- (2018) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
- (2018) Hiroki Nagai et al. International Journal of Clinical Oncology
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- The promise and challenges of immune agonist antibody development in cancer
- (2018) Patrick A. Mayes et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms of BCG immunotherapy and its outlook for bladder cancer
- (2018) Caroline Pettenati et al. Nature Reviews Urology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bispecific antibodies for cancer therapy: A review
- (2018) Anuradha Krishnamurthy et al. PHARMACOLOGY & THERAPEUTICS
- Toxicity profiles of immunotherapy
- (2018) S. Cousin et al. PHARMACOLOGY & THERAPEUTICS
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
- (2018) Laurence Zitvogel et al. SCIENCE
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
- (2018) Kristina Buder-Bakhaya et al. Frontiers in Immunology
- Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
- (2018) Marcus George Kwesi Cumberbatch et al. EUROPEAN UROLOGY
- The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
- (2018) Nick van Dijk et al. EUROPEAN UROLOGY
- Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
- (2018) Fatema A. Legrand et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.
- (2018) Neil Howard Segal et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Urothelial cancer: a narrative review of the role of novel immuno-therapeutic agents with particular reference to the management of non- muscle invasive disease
- (2018) E Doyle et al. BJU INTERNATIONAL
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
- (2018) Nicolas Delanoy et al. Lancet Haematology
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
- (2017) Marko Babjuk et al. EUROPEAN UROLOGY
- Recent progress in GM-CSF-based cancer immunotherapy
- (2017) Wan-Lun Yan et al. Immunotherapy
- Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
- (2017) Yasuhiro Fujisawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy
- (2017) David D. Chism Journal of the National Comprehensive Cancer Network
- An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
- (2017) Takahiro Karasaki et al. Journal of Thoracic Oncology
- A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
- (2017) Nora Sundahl et al. Journal of Translational Medicine
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- (2017) Daniel P Petrylak et al. LANCET
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Unlocking bladder cancer
- (2017) Chris Berdik NATURE
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
- (2017) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
- (2017) Ashish M. Kamat et al. Nature Reviews Urology
- Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
- (2017) Kenneth M. Felsenstein et al. Nature Reviews Urology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
- (2017) Abhishek D. Garg et al. TRENDS IN IMMUNOLOGY
- Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
- (2017) Martin Lauss et al. Nature Communications
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
- (2017) Alexandra Snyder et al. PLOS MEDICINE
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
- (2017) Kathrin Renner et al. Frontiers in Immunology
- Global Manufacturing of CAR T Cell Therapy
- (2017) Bruce L. Levine et al. Molecular Therapy-Methods & Clinical Development
- Oncolytic Viruses in Cancer Treatment
- (2017) Sean E. Lawler et al. JAMA Oncology
- Biomarkers for immunotherapy in bladder cancer: a moving target
- (2017) David H. Aggen et al. Journal for ImmunoTherapy of Cancer
- Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
- (2017) M. K. Callahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
- (2016) Archana Anantharaman et al. BMC CANCER
- Microbiome and Anticancer Immunosurveillance
- (2016) Laurence Zitvogel et al. CELL
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Future directions in bladder cancer immunotherapy: towards adaptive immunity
- (2016) Sean G Smith et al. Immunotherapy
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
- (2016) Matthew I. Milowsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select
- (2016) Charles G. Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
- (2016) Yoshio Nakamura et al. Oncotarget
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
- (2016) Kevin K. Dobbin et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
- (2015) A. Ghasemzadeh et al. CLINICAL CANCER RESEARCH
- A precision, personalized approach to the management of bladder cancer
- (2015) Andrea B. Apolo et al. CURRENT OPINION IN UROLOGY
- Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients
- (2015) Paolo Gontero et al. EUROPEAN UROLOGY
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Cancer and the microbiota
- (2015) W. S. Garrett SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Cancer nanomedicine: from targeted delivery to combination therapy
- (2015) Xiaoyang Xu et al. TRENDS IN MOLECULAR MEDICINE
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Oncogenic cancer/testis antigens: prime candidates for immunotherapy
- (2015) Morten F. Gjerstorff et al. Oncotarget
- Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
- (2015) Nicola E Annels et al. Journal for ImmunoTherapy of Cancer
- Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
- (2014) Jason W. Griffith et al. Annual Review of Immunology
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- The mechanism of action of BCG therapy for bladder cancer—a current perspective
- (2014) Gil Redelman-Sidi et al. Nature Reviews Urology
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- High-throughput identification of antigen-specific TCRs by TCR gene capture
- (2013) Carsten Linnemann et al. NATURE MEDICINE
- BCG immunotherapy for bladder cancer—the effects of substrain differences
- (2013) Christine Gan et al. Nature Reviews Urology
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Macrophage plasticity and polarization in tissue repair and remodelling
- (2012) Alberto Mantovani et al. JOURNAL OF PATHOLOGY
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
- (2011) Marko Babjuk et al. EUROPEAN UROLOGY
- Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review
- (2011) Tahlita C.M. Zuiverloon et al. EUROPEAN UROLOGY
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Signatures of Environmental Genetic Adaptation Pinpoint Pathogens as the Main Selective Pressure through Human Evolution
- (2011) Matteo Fumagalli et al. PLoS Genetics
- Pathological stage review is indicated in primary pT1 bladder cancer
- (2010) Bas W.G. Van Rhijn et al. BJU INTERNATIONAL
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
- (2009) K. S. Peggs et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
- (2009) Claudia Wrzesinski et al. JOURNAL OF IMMUNOTHERAPY
- Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer
- (2008) K. I. Al-Shibli et al. CLINICAL CANCER RESEARCH
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started